# Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)

> **NCT04893356** · — · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 75 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **GENETIC:** O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients

## Key facts

- **NCT ID:** NCT04893356
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-20
- **Primary completion:** 2022-02-28
- **Final completion:** 2025-01-20
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893356, "Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04893356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*